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1. Introduction 
Noninvasive imaging methods, including positron emission tomography (PET), have 
become essential for diagnosis and staging of gliomas, and monitoring of treatment 
response. The utility of these techniques have been found to be highly dependent on tumor 
grade. According to the World Health Organization (WHO) classification of tumors 
(Kleihues and Sobin 2000), gliomas are classified into 3 main histological types: astrocytoma, 
oligodendroglioma and glioblastoma. These histological types are further classified on the 
basis of anaplasia and degree of malignancy as: grade I, noninvasive glioma (pilocytic 
astrocytoma); grade II, less-invasive glioma (astrocytomas and oligodendrogliomas); grade 
III, invasive glioma (analplastic astrocytoma/oligodendrogliomas); and grade IV, highly 
invasive glioma (glioblastoma, or GBM).  
Low-grade gliomas (grade I and II) typically affect younger patients. Grade I glioma is the 
most common form of glioma in children and is less frequent in adults (Burkhard et al. 2003) 
while grade II gliomas are common in adults (mean age of onset is 40 years) (Hagerstrand et 
al. 2008). Median survival for low-grade glioma is varied but prognosis and treatment 
require regular follow ups. Low-grade gliomas grow slowly or stabilize spontaneously and 
with surgical resection, median survival can be 20 years or more (Burkhard et al. 2003). For 
high-grade gliomas, the mean age of onset is 40 years for grade III glioma and 61 years for 
GBM (Ohgaki and Kleihues 2005). GBM is the most malignant and most common glioma, 
accounting for 45% - 50% of all adult gliomas. Median survival for grade III glioma is 2-3 
years and for GBM is 1 year (Chen 2007). For optimal disease prognosis, treatment and 
follow up, one should be able to delineate the tumor lesion and most importantly, 
differentiate benign lesions from neoplastic lesions, low-grade from high grade tumors, and 
tumor progression from therapy induced necrosis. As will be discussed later, efforts are also 
being directed toward defining early imaging predictors of response to therapy. 
Conventional imaging with magnetic resonance imaging (MRI) provides excellent 
anatomical definition of brain tumors. MRI is highly sensitive in identifying lesions, mass 
effect, edema, hemorrhage, necrosis and signs of increased intracranial pressure (Chen 
2007). Pathologic changes are characterized on MRI by increased water content (edema) and 
blood-brain barrier (BBB) disruption, visualized as contrast enhancement (Grosu et al. 2002). 
Most tumors (low-grade or high-grade) have prolonged T1 and T2 relaxation times and thus 
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appear hypointense on T1-weighted images but hyperintense on T2-weighted images 
relative to normal brain (Grosu et al. 2002; Sartor 1999). In low-grade gliomas, peritumoral 
edema is minimal or absent and no contrast enhancement is seen due to intact BBB. 
Whereas, in high-grade gliomas, peritumoral edema is frequently seen and the tumor 
lesions usually show contrast enhancement, correlated with the extent of neovascularization 
and loss of integrity of the BBB owing to tumor infiltration and production of vascular 
endothelial growth factor. The anatomical features obtained by MRI are not sufficient to 
differentiate low-grade from high-grade gliomas with intact BBB, tumor lesions from 
inflammatory or vascular processes, and post-operative residual/relapse from necrosis 
(Chen 2007). 
In contrast to MRI, positron emission tomography (PET) provides unique functional 
information of tumors on a range of biological processes such as glucose metabolism, 
protein/DNA synthesis, cell proliferation, membrane synthesis, angiogenesis and oxygen 
tension that can reflect the changes in neoplasm (Basu and Alavi 2009). Assessment of the 
status of these processes in areas of interest in brain has been shown to be helpful in 
detection and grading of gliomas, delineation of tumor margins, disease prognosis and 
treatment. PET has also been useful in differentiating post-operative residual tumor from 
therapy induced necrosis and edema. This review discusses radiopharmaceuticals and 
progress in the development of PET techniques for imaging of gliomas in the following 
areas: glucose uptake, amino acid transport, cellular proliferation rate, choline uptake, 
somatostatin receptor density, angiogenesis and hypoxia.  
2. Glucose-based probes 
Increased glucose uptake and glycolysis are hallmark characteristics of a variety of 
neoplasms (Pedersen 2007; Warburg 1956). This makes radiolabeled glucose analogs logical 
tracers of choice for imaging of tumors. The radiofluorinated analog of glucose, 
[18F]fluorodeoxyglucose, or [18F]FDG, is the most common PET tracer for clinical PET 
oncology studies. A practical synthesis, suitable half-life (T1/2=109.7 min), negligible 
circulating metabolites, and well-established kinetics of uptake and retention of [18F]FDG 
makes it a preferred imaging probe in cancer imaging (Spence et al. 1998). [18F]FDG is 
transported into cancer cells by glucose transporters (GLUT1 and GLUT3) and, like glucose, 
it is phosphorylated via hexokinase to form [18F]fluorodeoxyglucose-6-phosphate. However, 
in contrast to glucose-6-phosphate, [18F]fluorodeoxyglucose-6-phosphate is very slowly 
metabolized further and hence is effectively trapped in the cancer cell (Spence et al. 1998). 
The trapped [18F]FDG-6-phosphate can be detected by [18F]FDG-PET thereby allowing non-
invasive evaluation of glucose uptake and glycolysis. In general, [18F]FDG-PET performs 
well in identifying highly malignant, high-grade gliomas because they typically exhibit 
higher glycolysis rates than the normal cerebral cortex (Di Chiro et al. 1982, 1987a). Di Chiro 
et al. (1985, 1987a, 1987b) were first to correlate [18F]FDG uptake with WHO grading of 
gliomas on the basis of a semiquantitative index of the ratio of [18F]FDG uptake in tumor to 
the average [18F]FDG uptake in normal cerebral cortex. [18F]FDG uptake ratio in high-grade 
glioblastoma was almost twice that of low-grade gliomas. In a different study, Delbeke et al. 
(1995) reported that high-grade gliomas can be detected with high sensitivity of 94% and 
specificity of 77% when tumor-to-white matter ratios exceed 1.5, and tumor-to-grey matter 
ratios exceed 0.6. In addition,[18F]FDG-PET was able to indicate anaplastic transformation of 
grade II gliomas into grade III gliomas by an increase in 18F-FDG uptake (Chen 2007). 
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[18F]FDG-PET has also been useful to differentiate hypoglycolytic non-malignant 
toxoplasmosis common in AIDS patients from hyperglycolytic CNS lymphoma (Hoffman et 
al. 1993).  
Assessment of [18F]FDG uptake in gliomas has high prognostic value (Di Chiro 1987). De 
Witte et al. (1996) studied 28 patients with histologically proven low-grade gliomas 
with [18F]FDG–PET and followed progression of disease for a mean of 27 months. All 19 
patients with tumors that were hypoglycolytic on PET were alive at the end of the follow-up 
period, whereas 6 of 9 patients with hyperglycolytic patterns on PET died. The prognostic 
utility of [18F]FDG–PET has been confirmed in several other studies (Alavi et al. 1988; Barker 
et al. 1997; Padma et al. 2003; Patronas et al. 1985). 
Although [18F]FDG-PET is accurate to detect high-grade gliomas, it has limited usefulness in 
detection of low-grade gliomas and some high-grade gliomas such as post-operative 
residual and recurrent glioma (Olivero et al. 1995; Ricci et al. 1998). Since glucose is the 
preferred fuel in normal brain, high [18F]FDG uptake in surrounding normal tissues in brain 
is unavoidable (Di Chiro et al. 1982). Low grade gliomas tend to have the same or lower 
[18F]FDG uptake as compared to average [18F]FDG uptake in white matter, thus resulting in 
false negative readings (Kawai et al. 2005). This is also true for certain high-grade gliomas, 
especially hypoglycolytic residual (Padma et al. 2003) and recurrent tumors (Chao et al. 
2001) that may exhibit less or similar [18F]FDG uptake to average [18F]FDG uptake in grey 
matter. In addition, in the case of patients with Alzheimer disease and epilepsy, affected 
regions in brain can show decreased [18F]FDG uptake compared to background (Fazekas et 
al. 1989; McGeer et al. 1986). On the other hand, brain regions with abscess or acute necrosis 
occurring hours of weeks after radiotherapy, chemotherapy can show increased [18F]FDG 
uptake compared to background leading to false positive readings (Floeth et al. 2006). Thus, 
low tumor-to-normal background radioactivity concentration (T/N) ratios and difficult to 
interpret contrasts between normal and pathological regions limit the specificity of 
[18F]FDG-PET to detect low-grade and residual or relapsed high-grade brain tumors.  
Given these concerns, attempts have been made to improve the accuracy of [18F]FDG for 
imaging of gliomas. In cases where T/N (white or grey matter) ratios for [18F]FDG uptake 
are not useful for delineating low-grade, residual or relapsed high-grade glioma, two 
strategies have been reported to help: (1) co-registration of [18F]FDG–PET images with MR 
images (Chao et al. 2001; Wang et al. 2006) and (2) delayed [18F]FDG–PET imaging (Spence 
et al. 2004). Co-registration and interpretation of [18F]FDG–PET images with MR images 
can improve the performance of [18F]FDG–PET (Figure 1) for detecting low-grade 
(Borgwardt et al. 2005; Wong et al. 2004), residual or relapsed high-grade gliomas (Chao et 
al. 2001; Wang et al. 2006). Low grade gliomas can be identified by similar [18F]FDG uptake 
to white matter in regions with increased signal on T2-weighted MRI (Borgwardt et al. 2005; 
Wong et al. 2004), while recurrent high grade gliomas are often indicated as [18F]FDG 
uptake in regions with contrast enhancement on T1-weighted MRI (Chao et al. 2001; Wang 
et al. 2006). Delayed PET imaging, as proposed by Spence et al. (2004), is another strategy to 
improve the contrast between tumor lesion and background. In this study, nineteen patients 
with gliomas were imaged from 0 to 90 min and once or twice at 3–8 h after injection. In 12 
of 19 patients, visual analysis of delayed images up to 8 h after injection showed these 
images to better distinguish relapsed tumors in grey matter (Figure 2). Standardized uptake 
values (SUVs) were also greater in tumors than in normal grey or white matter on delayed 
imaging. Using kinetic modeling, they demonstrated that the rate constant of 
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[18F]fluorodeoxyglucose-6-phosphate degradation (k4) was not significantly different 
between tumor and normal brain tissue for shorter datasets but was lower in tumor than in 
normal brain tissue for the longer dataset (8 h), suggesting that higher 
[18F]Fluorodeoxyglucose-6-phosphate degradation rates are present in normal brain tissue 
than tumor. Since this report, other studies have shown the utility of delayed PET imaging 
for delineating brain tumors (Farid et al. 2009; Kim et al. 2010). 
 
 
Fig. 1. A patient who had received surgery, radiation, and chemotherapy for anaplastic 
astrocytoma. Axial gadolinium-enhanced T1-weighted image (left) demonstrates nodular 
enhancement posterior to the surgical resection cavity. Co-registered [18F]FDG-PET image 
demonstrates increased [18F]FDG activity corresponding to this region, similar to gray 
matter, compatible with recurrent tumor. Correlation of the MRI and PET imaging findings 
is necessary to make this determination, and accurate image co-registration is essential. 
 
 
Fig. 2. A 45-year-old woman with recurrent right temporal GBM. T1-weighted gadolinium-
enhanced (T1Gd) MRI showing contrast enhancement in right temporal region of the brain. 
[18F]FDG–PET scan with much more prominent T/N delineation in this right temporal 
region at the later time point, 473 min (~8 h), compared to 90 min (1.5 h). Image reproduced 
from work by Spence et al. (2004) and used with permission. 
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3. Amino acid-based probes 
Amino acids play a central role in protein synthesis and intermediary metabolism (Cellarier 
et al. 2003; Morowitz et al. 2000). The enhanced uptake of essential amino acids into 
neoplasms through specific amino acid transporters has motivated the design and 
evaluation of a large number of positron-labeled essential amino acid analogs. In addition, 
the low uptake of essential amino acids in normal brain tissue relative to tumor tissue 
renders amino acid tracers advantageous for imaging gliomas (Lilja et al. 1985). The most 
studied essential amino acid tracers are [11C]methionine ([11C]MET), [18F]fluoroethyl-L-
tyrosine ([18F]FET) and 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine ([18F]FDOPA). 
3.1 [
11
C]MET  
Increased uptake of methionine by cancer cells results from increased transport flux, 
primarily by L-amino acid transporters, enhanced protein synthesis, increased need for 
polyamines, and a high rate of trans-methylation and trans-sulfuration reactions (Leskinen-
Kallio et al. 1991). [11C]MET uptake in tumor lesions is not dependent on disruption of the 
BBB (Roelcke et al. 1995; Sasajima et al. 2004). This is a major advantage compared to MRI 
where contrast enhancement for detection of tumor lesions is dependent on BBB disruption. 
Studies with [11C]MET-PET have shown that amino acid tracer, [11C]MET, accumulates in all 
gliomas, including low-grade glioma that are difficult to detect on contrast-enhanced MRI 
and [18F]FDG-PET (Ogawa et al. 1993). 
[11C]MET-PET can be used to predict histological grades of gliomas. Lilja et al. (1985) 
evaluated 14 patients with gliomas and found that [11C]MET-PET could differentiate high-
grade glioma from low-grade glioma on the basis of T/N ratio. The ratio of the uptake of 
[11C]MET in high-grade tumors was 1.9-4.8 and low-grade tumor was 0.8-1.0. Derlon et al. 
(1989) too confirmed positive correlation of T/N ratio with the histological grade of gliomas. 
Later study with large set of 196 patients, Herholz et al. (1998) showed that [11C]MET could 
differentiate among high-grade gliomas, low-grade gliomas, and chronic or subacute 
nontumoral lesions. In this study, [11C]MET-PET was also useful in detecting recurrent or 
residual tumors as they showed higher [11C]MET uptake than primary gliomas. 
[11C]MET-PET has been shown to have high prognostic potential. Kaschten et al. (1998) 
performed [18F]FDG-PET and [11C]MET-PET in 54 patients with gliomas. [11C]MET was 
superior to [18F]FDG in predicting the histologic grade and prognosis of gliomas. With a 
larger set of 85 patients, De Witte et al. (2001) applied qualitative and quantitative scoring 
systems for [11C]MET uptake. Both scoring systems confirmed the prognostic importance of 
[11C]MET-PET. In this study, gliomas were histologically graded following [11C]MET-PET 
guided resection (42 cases) or stereotactic biopsy (43 cases). Uptake of [11C]MET was present 
in 98% of the gliomas studied. The T/N ratio was significantly correlated with the 
histological grade of glioma. A statistically poor patient outcome was demonstrated during 
follow-up when this ratio was higher than a threshold of 2.2 for grade II gliomas and 2.8 for 
grade III gliomas. A high [11C]MET uptake was statistically associated with short survival 
times. Better prognostic utility of [11C]MET-PET relative to [18F]FDG-PET was also shown in 
other studies (Kim et al. 2005; Van Laere et al. 2005). 
[11C]MET-PET is also useful to differentiate recurrent tumor from post-operative radiation 
injury (Gehrke et al. 1991; Ogawa et al. 1991; Sonoda et al. 1998). Tsuyuguchi et al. (2003) 
examined 21 adult patients with [11C]MET-PET to differentiate radiation necrosis from 
recurrent metastatic brain tumor following stereotactic radiosurgery. They observed mean 
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T/N ratio and mean SUV for [11C]MET to be 1.15 and 1.78, respectively, in the radiation 
necrosis group (12 cases); and 1.62 and 2.5, respectively, in the tumor recurrence group (9 
cases). The sensitivity and specificity of [11C]MET-PET for detection of tumor recurrence 
were determined to be 77.8% and 100%, respectively. In a separate study, [11C]MET-PET 
was shown to be superior to [18F]FDG-PET in detecting recurrent brain lesions (Chung et al. 
2002). A recent study by Okamoto et al. (2010) further confirmed the utility of [11C]MET-PET 
to detect recurring lesions. Mean T/N ratio of all recurrent tumors and necrosis were 
1.98 ± 0.62 and 1.27 ± 0.28, respectively (p < 0.01) (Okamoto et al. 2010). In smaller lesions 
(20 – 30 mm), T/N ratio for recurrent tumor (1.72 ± 0.44) was also significantly higher than 
that for necrosis (1.20 ± 0.11) (p < 0.01) (Okamoto et al. 2010). Thus, [11C]MET-PET provides 
high diagnostic value for recurring tumor lesions, with particular value in early diagnosis of 
recurrence.  
3.2 [
18
F]FET 
Wester et al. (1999) were the first to introduce the fluorinated tyrosine analog [18F]FET for 
imaging gliomas. The longer half-life of 18F (109.7 min) relative to 11C (20 min) is more 
practical for production and distribution to multiple PET scanning facilities. The high in vivo 
stability of [18F]FET, fast brain and tumor uptake kinetics, low accumulation in non-tumor 
tissue, and ease of synthesis strongly supported evaluation of [18F]FET as an amino acid 
tracer for imaging gliomas.  
Weber et al. (2000) compared uptakes of [18F]FET and [11C]MET by gliomas in 13 patients. 
On the basis of the [11C]MET-PET, viable tumor tissue were delineated in all 13 patients. The 
same tumors showed rapid uptake of [18F]FET with high image contrast. The mean uptake 
(SUV) of [11C]MET was slightly higher than [18F]FET in normal grey matter ( 1.4 ± 0.2 for 
[11C]MET and 1.1 ± 0.2 for [18F]FET); normal white matter (0.9 ± 0.1 for [11C]MET and 0.8 ± 
0.2 for [18F]FET); and tumor lesions (3.3 ± 1.0 for [11C]MET, 2.7 ± 0.8 for [18F]FET). However, 
contrast between tumor and normal tissue background was not significantly different 
between [11C]MET and [18F]FET (Figure 3). In comparison to [18F]FDG-PET, a recent study 
found [18F]FET-PET was more accurate to detect malignant brain lesions, especially low-
grade gliomas (Lau et al. 2010). 
Although there is doubt on the potential of [18F]FET-PET for grading gliomas (Popperl et al. 
2004), a clinical study by Pauleit et al. (2005) showed that co-registration of [18F]FET-PET 
and MRI could significantly improve the sensitivity and specificity of tumor detection and 
correlation to histological grade of tumor. In addition, a separate study showed have shown 
that the kinetic profile of [18F]FET uptake for high- and low-grade lesions may be useful in 
grading tumors (Spence et al. 2004). In their study, tumors were classified into low (grade I 
and II) and high grade (grade III and IV) prior to [18F]FET-PET scans. A significant 
difference (p<0.05) in T/N ratio was observed between high-grade (ratio = 3.2) and low-
grade tumors (ratio = 2.0) in early time points (0-10 min post-injection). No significant 
differences were found at later time points (30-40 min post-injection). The importance of the 
kinetics of [18F]FET is not limited to grading primary tumor lesions. Low-grade recurrent 
tumors associated with good prognosis were differentiated from high-grade recurrent 
tumor associated with poor prognosis on the basis of kinetics of [18F]FET uptake (Popperl et 
al. 2006). 
A major strength of [18F]FET-PET is that it reliably distinguishes post-operative benign 
lesions from recurrent tumors (Popperl et al. 2004; Popperl et al. 2006). Popperal et al. (2004) 
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studied 53 patients with low grade (1 grade I, 9 grade II) or high grade gliomas (16 grade III, 
27 grade IV) and clinically suspected recurrent tumors. The patients underwent [18F]FET-
PET scans 4-180 months after various treatments. In the 42 patients with confirmed 
recurrence, there was additional distinct focal [18F]FET uptake with significantly higher 
values compared with those in the 11 patients without clinical signs of recurrence. 
 
 
Fig. 3. Patient with residual tumor after subtotal resection of GBM (top) and a patient with 
radiation induced changes after radiotherapy for metastatic melanoma (bottom). T1-
weighted contrast-enhanced MRI showing contrast enhancement in both residual tumor (A, 
top) and radiation induced injury (A, bottom). In the patient with residual GBM, [11C]MET-
PET (B, top) and [18F]FET-PET (C, top) shows markedly increased tracer uptake. However, 
there is no increased uptake of [11C]MET (B, bottom) and [18F]FET (C, bottom) in radiation 
induced injury. Image reproduced from work by Wolfgang A. Weber et al. (2000) and used with 
permission. 
3.3 [
18
F]FDOPA 
In mammalian cells, L-DOPA is synthesized from the amino acid, L-tyrosine, by the enzyme 
tyrosine hydroxylase (Kaufman 1995). L-DOPA is a precursor of the neurotransmitters: 
dopamine, norepinephrine, and epinephrine (Nagatsu 1995). L-DOPA is taken up by the brain 
through the blood-brain barrier (BBB) mediated by large neutral amino acid transporters 
(Lemmens et al. 2005). The [18F]fluorinated L-DOPA analog, [18F]FDOPA was initially 
developed as a radiotracer for use in patients with movement disorders (Heiss et al. 1996). In 
an early study, [18F]FDOPA-PET of a 57 y old patient revealed pathologically increased 
[18F]FDOPA accumulation in the right frontal lobe (Heiss et al. 1996). Unexpectedly, further 
PET examinations demonstrated increased [11C]MET uptake and low [18F]FDG uptake in this 
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right frontal region, suggesting a low-grade glioma lesion. MRI, 1H-MRSI and histological 
examination later confirmed presence of a grade II oligo-astrocytoma in the lesion.  
Following this incidental discovery, various studies were performed to evaluate the potential 
of [18F]FDOPA-PET for imaging of gliomas. Chen et al. (2006) compared [18F]FDOPA-PET with 
[18F]FDG-PET to evaluate the potential of [18F]FDOPA-PET to detect tumor lesions in patients 
with newly diagnosed or previously treated brain tumors. The [18F]FDOPA-PET images were 
acquired for 10–30 min post-injection. In this study, [18F]FDOPA-PET demonstrated excellent 
visualization of both low-grade and high-grade tumors, although the absolute uptake was not 
significantly different between the different tumor grades. [18F]FDOPA-PET was more 
sensitive and specific than [18F]FDG-PET for evaluating and distinguishing recurrent tumors 
from radiation necrosis. Specific transport of [18F]FDOPA (Lemmens et al. 2005) independent 
of disruption of BBB and low background activity rendered it superior to MRI and [18F]FDG 
for detecting recurrent gliomas. 
A number of subsequent studies have suggested that tumor grade does not significantly 
affect [18F]FDOPA uptake (Figure 4) (Chen et al. 2006; Duan et al. 2004; Jager et al. 2001; Li 
and Zhang 2004; Ono et al. 2004). However, Schiepers et al. (2007) used kinetic modeling of 
[18F]FDOPA time courses out to 75 min to show that high-grade tumors had significantly 
higher transport rate constant, k1, equilibrium distribution volumes, and influx rate 
constant K than did low-grade tumors (P< 0.01). A 3-compartment model with corrections 
for tissue blood volume, metabolites, and partial volume, suggested that [18F]FDOPA was 
transported but not trapped in tumors. The shape of the uptake curve appeared to be related 
to tumor grade. After an early maximum, high-grade tumors had a steep descending 
branch, whereas low-grade tumors had a slowly declining curve, like that for the cerebellum 
but on a higher scale. A high correlation was found between SUV in tumors and influx rate 
constant K, indicated that simple uptake measurements at 60-70 min should be sufficient in 
clinical practice for grading tumors.  
 
 
Fig. 4. Patient with newly diagnosed (A) GBM (B) Grade II oligodendroglioma. Tumor 
lesion shown as region with contrast enhancement in T1-weighted MRI (left). This region is 
not visible in [18F]FDG-PET scan (middle) but a prominent [18F]FDOPA uptake is seen in this 
region in [18F]FDOPA-PET scan (right). Image adapted from work by Wei Chen et al. (2006) and 
used with permission. 
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Potential use of [18F]FDOPA in tumor grading was also supported by a recent study by 
Chen et al. (2006) that showed significantly higher uptake in high-grade than in low-grade 
tumors in newly diagnosed tumors. This correlation was not seen in recurrent tumors that 
had been treated previously. In summary, [18F]FDOPA-PET has been found useful in 
detecting and differentiating recurrent tumors from radiation necrosis and may also have 
potential in grading newly diagnosed tumors, although more studies are needed to fully 
define the potential of [18F]FDOPA-PET. 
A number of other positron-labeled amino acid analogs have been developed for imaging of 
brain tumors, although having fewer clinical trials to determine their characteristics for 
imaging of gliomas. These include [124I]iodophenylalanine (Farmakis et al. 2008), 
[18F]fluoromethylphenylalanine (FMP), [18F]fluoroboronophenylalanine (FBP) (Hsieh et al. 
2005; Imahori et al. 1998), [18F]fluoroethylphenylalanine (FEP) (Wang et al. 2011) and 
[18F]fluoropropylphenylalanine (FPP) (Wang et al. 2011), and 1-Aminocyclobutane-1-
[11C]carboxylic acid (1-[11C]-ACBC) (Hubner et al. 1998). 
4. Choline-based probes 
In recent years, choline metabolism has received a growing interest in cancer research. 
Choline is incorporated into membrane phospholipid in the form of phosphatidylcholine 
through the multistep Kennedy pathway. Phosphatidylcholine is one of the major lipid 
components of plasma membranes in mammalian cells and is essential for membrane 
structural stability and cell proliferation. Following its transport into the cell, choline 
undergoes ATP-dependent phosphorylation to form phosphocholine, a reaction catalyzed 
by choline kinase. High levels of choline uptake and increased choline kinase activity 
relative to normal tissues have been reported in various cancers including brain tumors 
(Fulham et al. 1992). This has motivated the development of choline based PET imaging for 
noninvasive evaluation of gliomas. 
Shinoura et al. (1997) were the first to use choline as a PET tracer of brain tumor imaging. 
They evaluated 20 patients with brain tumors using [11C]choline PET. Progressive uptake of 
[11C]choline was observed in brain tumors, while uptake by surrounding normal cerebral 
cortex was 10-fold lower. Later, Ohtani et al. (2001) compared [11C]choline-PET with 
[18F]FDG-PET in 22 patients with histopathologically confirmed benign lesions and brain 
tumors from grade I-IV. Higher uptake of [11C]choline relative to [18F]FDG was observed in 
high-grade grade III and grade IV gliomas. Furthermore, [11C]choline was able to detect the 
extent of tumor better than MRI and could differentiate high-grade from low-grade lesions, 
but could not differentiate low-grade lesions from benign lesions. 
The short half-life of [11C]choline limits the use of this tracer to facilities having an on-site 
cyclotron. In view of this, a choline radiotracer with a longer half-life is highly desirable. 
[18F]Fluorinated analogs of choline [18F]FCH are promising options for choline based PET 
tumor imaging.  
DeGrado et al. (2001) first reported brain tumor imaging with [18F]FCH in a patient with 
previously resected anaplastic astrocytoma. The maximal T/N ratio of 10:1 was attained 
within 5 min after injection. [18F]FDG -PET revealed a corresponding area of increased 
[18F]FDG uptake; however, the tumor boundaries were difficult to assess with FDG because 
of high uptake by normal cortex. Hara et al. (2003) performed studies with 
[18F]fluoroethylcholine (FECH) in 12 glioma patients. The T/N ratio of [18F]FECH was 10.5-
12 in anaplastic astrocytoma and 13.2-21 in glioblastoma. These ratios were slightly higher 
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than those obtained with [11C]choline in the same patients. A preliminary study by Kwee et 
al. (2004) in 2 patients suggested that [18F]FCH uptake was significantly higher in 
glioblastoma multiforme (GBM) than benign demyelinating disease. Subsequently, Kwee et 
al. (2007) performed a more extensive [18F]FCH PET study on 30 consecutive patients (14 
women, 16 men; age range, 26-79 years) with solitary brain lesions defined by MRI. In this 
study, the order of SUV and T/N ratios were benign lesions < high-grade gliomas < 
metastases from distant tumors with appreciable separation of these classes. [18F]FCH is also 
useful in detecting recurrent GBMs (Figure 5). 
Pre-clinical studies on the in vivo kinetics and metabolism of [18F]FCH and choline in a 9L 
glioma allograft tumor model showed marked washout from the tumor possibly resulting 
from the hypoxic nature of these tumors. However, a strong association of [18F]FCH uptake 
and angiogenesis was found in the C6 glioma xenograft model (Wyss et al. 2007) and 
increased [18F]FCH uptake was observed in a multidrug resistant U87MG glioma tumor 
model (Vanpouille et al. 2009).  
 
 
Fig. 5. [18F]FCH uptake in recurrent GBM. PET/CT (left) and [18F] FCH-PET (right) image 
shows a 6 mm focus of increased [18F]FCH uptake along a right frontal lobe resection cavity. 
This lesion was noted to increase in size on serial brain MRI consistent with the diagnosis of 
recurrent tumor. A post-craniotomy defect is evident on the PET/CT image. [18F] FCH-PET 
is potentially advantageous for imaging brain tumors such as GBM given the low amounts 
of physiologic cerebral [18F]FCH uptake. Image Courtesy of Dr. Sandi A. Kwee, MD, Nuclear 
Medicine Department, Queen's Medical Center, Honolulu, HI, USA. 
5. Integrin-based probes 
Angiogenesis is a crucial process for tumor growth and metastasis (Kountouras et al. 2005). 
This process requires intracellular and extracellular interactions in which integrins play an 
important role (Brooks et al. 1994). Antagonists against alphav3 integrin have been shown to 
block angiogenesis and reduce tumor growth in preclinical animal models (MacDonald et al. 
2001) and clinical trials (Carter 2010). This integrin is a membrane bound receptor that 
mediates intracellular signal transduction by recognizing and binding to Arg-Gly-Asp 
(RGD) containing proteins in the extracellular matrix (Main et al. 1992). On binding to 
different types of RGD containing protein, it senses the external microenvironment and 
accordingly regulate cellular shape, mobility and cell cycle progression along with 
angiogenesis and metastatsis (Brooks et al. 1994). Alphav3 integrin is expressed at low 
levels on epithelial cells and mature endothelial cells but highly expressed on activated 
endothelial cells of the neovasculature of gliomas (Liu 2009). Its expression correlates well 
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with tumor progression and invasiveness of gliomas (Bello et al. 2001). Therefore, this 
integrin has received attention as a target for imaging probe development.  
The most common integrin-targeting radiopharmaceuticals are radiolabeled RGD 
containing peptides. Cyclic RGD peptides (cRGD peptides) are preferred over linear RGD 
peptides due to their higher metabolic stability (Bogdanowich-Knipp et al. 1999). However, 
radiolabeled cRGD peptides (18F-FB-cRGDs (Chen et al. 2004) and 64Cu-DOTA-cRGDs (Chen 
et al. 2004)) commonly suffer the drawback of poor tumor retention and high renal and/or 
hepatic uptake. To improve the tumor imaging properties of these tracers, dimeric (Chen et 
al. 2004) and tetrameric (Wu et al. 2005) cyclic RGD congeners have been developed. The 
multimeric cyclic RGD probes showed higher tumor uptake but nevertheless exhibited 
rapid uptake by liver and kidneys. To decrease uptake in liver and kidneys, modifications 
such as glycosylation (Schnell et al. 2009) or PEGylation (Chen et al. 2004) have helped to 
achieve higher uptake in tumors along with decreased uptake in liver and kidney in U87MG 
glioblastoma models (Chen et al. 2004; Chen et al. 2004; Wu et al. 2005) and in patients with 
de novo or recurrent GBM (Schnell et al. 2009). 
New developments to integrin imaging are in progress. Recently, a new generation of RGD 
containing probes have been designed that show better potential for imaging gliomas. The 
new approach is based on cystine knot proteins or knottins that are relatively stable in 
physical, chemical and biological environments due to presence of scaffold of disulfide-
bonded framework and a triple-stranded ß-sheet fold (Kimura et al. 2009). The Knottin 
family members also possess one or more surface-exposed loops that can tolerate sequence 
diversity. RGD peptides have been grafted into these surface-exposed loops, while 
radiolabeling accomplished with conjugation of PET radionuclide, 18F-FB or 64Cu-DOTA. In 
a U87MG glioblastoma model, a knottin based probe demonstrated rapid and high tumor 
accumulation, fast clearance from blood and normal organs, and low uptake in the kidney 
and liver (Miao et al. 2009).  
6. Cellular proliferation probes 
Increased cellular proliferation is an integral part of the cancer phenotype (Bading and 
Shields 2008). The primary requirement for cell proliferation is replication of nuclear DNA. 
Of the 4 nucleotides (adenine, guanine, cytosine and thymidine) required for DNA 
synthesis, thymidine is the only one that is specific for DNA. In cells, thymidine is derived 
either de novo or through the salvage pathway (Bading and Shields 2008). The de novo 
pathway is not a viable alternative for monitoring DNA synthesis in proliferating cells 
because the relevant precursors (deoxyuridine, uridine, and uracil) are routed into both 
DNA and RNA (Bading and Shields 2008). Thus, thymidine salvage pathway is a better 
choice for indication of proliferation. PET radiotracers of thymidine have been developed, 
including [11C]thymidine ([11C]TdR) (De Reuck et al. 1999) and 3'-deoxy-3'-fluorothymidine 
([18F]FLT). These probes are currently being evaluated for their potential for imaging cellular 
proliferation in gliomas. The thymidine-based tracers are transported into cells and 
subsequently phosphorylated by thymidine kinase-1 (TK-1), thereby rendering them 
trapped within the cell. Since TK-1 activity correlates to a significant extent with the cellular 
proliferation rate, the PET-measurement of tissue retention of radioactivity is a non- 
invasive indicator of proliferation. The advantage of using the fluorinated thymidine tracer 
[18F]FLT over [11C]TdR is twofold. First, replacement of the hydroxy group of 
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deoxyribose with radiofluorine makes it resistant to degradation (Shields et al. 1998) and 
second, the longer half-life of 18F is more practical for clinical imaging. 
Increased glucose metabolism in inflammatory tissues and other non-specific lesions is the 
main source of false-positive [18F]FDG-PET findings in oncology. Van Waarde et al. (2004) 
used a rodent model with C6 glioma tumor and inflammatory lesion to show that [18F]FLT 
was more specific than [18F]FDG for uptake by glioma lesions relative to inflammation. 
However, the ability of [18F]FLT to detect tumors was dependent on disruption of the BBB 
(Muzi et al. 2006), rendering it more suitable for detecting high-grade gliomas than low-
grade ones. In a separate clinical study (Chen et al. 2005), [18F]FLT–PET was more sensitive 
than [18F]FDG-PET for imaging recurrent high-grade tumors, correlated better with the Ki-
67 proliferation index and was a more powerful predictor of tumor progression and 
survival. The reason for superiority of [18F]FLT–PET over [18F]FDG–PET was low [18F]FLT 
uptake in the normal brain tissue leading to higher T/N contrast (Figure 6). When 
compared with [11C]MET, Jacobs et al. (2005) showed that [18F]FLT was less sensitive in 
detecting tumors than [11C]MET, especially for low-grade astrocytomas. Nevertheless, 
Kawai et al. (2009) found a high correlation between histological tumor grade and [18F]FLT 
uptake in gliomas. A significant difference in SUVmax of [18F]FLT was observed between 
grade II (0.27 ± 0.06, n=6) and grade IV (2.18 ± 0.93, n=10) gliomas (P < 0.0001), and grade III 
(0.70 ± 0.45, n=7) and grade IV gliomas (P < 0.001). Importantly, [18F]FLT uptake correlated 
significantly better with the Ki-67 index (r = 0.86, P < 0.0001) than did methionine uptake in 
gliomas. Studies have also reported the use of [18F]FLT-PET in investigating the 
effectiveness of therapy and prognosis of gliomas (Chen et al. 2007; Kawai et al. 2009). 
Increased [18F]FLT accumulation is also observed in other brain tumors including malignant 
lymphoma (Kawai et al. 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Patient with glioblastoma. FLT-PET scan (A) and contrast-enhanced MRI (B) of 
biopsy-proven glioblastoma multiforme (GBM) in a 58 year-old female, just prior to the 
initiation of chemoradiation. Thick black arrow points to the highly proliferative rim of 
tumor surrounding a photopenic region of central necrosis. FLT uptake in the normal brain 
parenchyma is minimal, allowing a favorable lesion-to-background ratio. Physiologic 
uptake is also seen within the bone marrow (short thin arrow) and scalp (long thin arrow) 
Image Courtesy of Dr. Laura Horky, Brigham and Women’s Hospital, Boston. 
Another strategy for imaging of cell proliferation in tumor lesions involves non-invasive 
assessment of the concentration of sigma receptors in cells using sigma-receptor ligands 
BA
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(Wheeler et al. 2000). Sigma-receptors are expressed more in proliferating tumor cells than 
in quiescent tumor cells (Wheeler et al. 2000). Using a preclinical tumor model, Van Waarde 
et al. (2004) were the first to report feasibility of using sigma-receptor binding ligands, 
[11C]SA4503 and [18F]FE-SA5845 for detecting gliomas. It is known that tumors are 
heterogenous in nature, including areas of low and high proliferation rates. The proportion 
of cells with low proliferation rate increases with increase in tumor size, especially in the 
necrotic center. In the C6 glioma rat model, tumor uptake of [18F]FE-SA5845 showed a 
negative correlation with tumor size (P < 0.0001), in contrast to that of [11C]SA4503, 
suggesting that tissue binding of [18F]FE-SA5845 is solely related to cellular proliferation. 
Later Van Waarde et al. (2006) compared the bio-distribution of 4 PET tracers ([11C]SA4503, 
[18F]FE-SA5845, [11C]choline and [11C]MET) with previously published bio-distribution data 
of [18F]FLT and [18F]FDG in C6 glioma rat tumor model. In their study, sigma-receptor 
ligands and [18F]FLT were more tumor selective than [18F]FDG, [11C]choline, or [11C]MET in 
the C6 glioma model. However, [11C]SA4503 and [18F]FE-SA5845 were less sensitive than 
were [11C]choline, [11C]MET, and [18F]FDG. Clinical PET studies for evaluation of sigma 
receptor expression in gliomas are ongoing. 
7. Somatostatin-based probes 
Meningiomas are the most common non-glial primary tumors of the central nervous system 
accounting for approximately 15% of all intracranial tumors (Buetow et al. 1991). More than 
90% of intracranial meningiomas are slow growing and histopathologically benign but 
malignant meningiomas are not rare (Buetow et al. 1991; Goldsmith et al. 1994). [18F]FDG 
uptake in tumor lesions is dependent on glycolytic rate and disruption of blood brain barrier 
(Roelcke et al. 1995). High expression of the somatostatin receptor (SSTR) subtype 2 (Dutour 
et al. 1998) in meningiomas offer the possibility of receptor-targeted imaging (Henze et al. 
2005; Henze et al. 2001) of meningiomas. In the case of meningiomas with low glycolytic 
rate and intact BBB (Roelcke et al. 1995), somatostatin receptor based tracers might be more 
useful for tumor detection and disease management than [18F]FDG. In a clinical study, a 
somatostatin receptor analog, 68Ga-DOTA-D-Phe1-Tyr3-octreotide (DOTA-TOC) labeled with 
the positron emitter 68Ga (half-life, 68 min) was evaluated for imaging meningioma (Henze 
et al. 2001). In contrast to [18F]FDG, this ligand showed higher T/N uptake ratios. The initial 
results are encouraging but more clinical studies are needed to fully assess the potential of 
somatostatin receptor based tracers for imaging meningiomas. 
8. Hypoxia-based probes 
Hypoxia, a hallmark of aggressive tumor behavior often noted in high grade glioblastomas, 
is associated with resistance to therapy, poorer survival, invasion and aggressiveness (Szeto 
et al. 2009). Estimation of hypoxia could be an important determinant of overall survival in 
several tumors including gliomas. PET imaging with the hypoxia radiotracer 
[18F]fluoromisonidazole ([18F]FMISO) presents a possible means of noninvasively detecting 
tumor hypoxia in gliomas (Rasey et al. 2000; Valk et al. 1992). In a preclinical C6 glioma 
tumor model study (Tochon-Danguy et al. 2002), [18F]FMISO uptake was significantly 
higher in tumor tissue compared to normal brain and the uptake was independent of tumor 
size. [18F]FMISO uptake was observed homogeneously throughout viable glioma tissue in 
tumor sizes ranging from 2 mm to almost 1 cm. Quantitation of uptake of [18F]FMISO 
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showed a tumor-to-brain ratio of 1.9 and a tumor-to-blood ratio of 2.6 at 2 hours post-
injection. In a recent clinical study by Shibahara et al. (2010), 8 patients with gliomas of 
different grades underwent PET studies with a new imidazole based hypoxia imaging 
agent, 1-(2-[18F]fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole ([18F]FRP-170). 
The new agent showed higher image contrast and faster clearance than [18F]FMISO. 
[18F]FRP-170 images showed positive correlation with HIF-1 expression, a weak correlation 
with [18F]FDG-PET and MR, but no correlation with [11C]MET-PET. The [18F]FRP-170-PET 
images showed marked uptake in the 3 GBM, and moderate uptake in recurrent anaplastic 
astrocytoma and oligodendroglioma, but no uptake in the other tumors (oligodendroglioma 
and diffuse astrocytoma). It is suggested that the use of hypoxia markers in patients with 
primary or recurrent gliomas could potentially assist in defining hypoxic tumor regions and 
predicting response to radiotherapy, but is not effective for grading tumors. 
9. Acetate-based probes 
Acetate is transported into the cell via the monocarboxylic acid transporter where it is 
converted in mitochondria to acetyl-coenzyme A (acetyl-CoA) (Lopresti and Mason 2009). 
Acetyl-CoA is a substrate for several biochemical pathways, most notably the tricarboxylic 
acid (TCA) cycle, and for glutamine and lipid synthesis. Additional studies have 
demonstrated that the preferential use of acetate by astrocytes is mediated by transport, 
although the exact mechanism is not fully understood (Lopresti and Mason 2009). In a 
clinical study, Yamamoto et al. (2008) evaluated [11C]acetate for detecting brain gliomas and 
differentiating high-grade gliomas. Sensitivities of [11C]acetate, [11C]MET, and [18F]FDG 
were 90%, 100%, and 40%, respectively. The T/N ratios of [11C]acetate and [11C]MET were 
significantly higher than that of [18F]FDG. With respect to tumor grades, uptakes (SUVs) of 
[11C]acetate and [18F]FDG in high-grade gliomas were significantly higher than those in low-
grade gliomas while no significant differences were observed with [11C]MET. In another 
clinical study (Tsuchida et al. 2008), [11C]acetate was superior to [18F]FDG in differentiating 
high-grade tumors from low-grade tumors. In a recent preclinical animal study (Marik et al. 
2009), the fluorinated form of acetate, [18F]fluoroacetate, was evaluated for the assessment of 
several neuropathologies including glioblastoma represented by the orthotopic U87 
xenografts, ischemia associated with stroke or hypoxia. In this study, [18F]fluoroacetate 
showed the highest T/N ratio in glioblastoma followed by stroke-ischemia and hypoxia-
ischemia. 
10. Conclusions 
PET imaging offers a growing “toolbox” of molecular imaging probes for noninvasive 
evaluation of gliomas. In general, [18F]FDG-PET has high prognostic value, performs well in 
identifying anaplastic transformations and detecting malignant high grade gliomas. But due 
to high normal cerebral uptake, it has limited use in detection of low-grade gliomas and 
residual/recurrent gliomas. Amino acid based probes (e.g, [11C]MET, [18F]FET and 
[18F]FDOPA) have low normal cerebral uptake, resulting in improved detection of low-
grade lesions. They have shown utility for grading of gliomas and they can differentiate 
residual/recurrent tumor from post-operative radiation injury. Preclinical studies with 
sigma receptor ligands suggest them to be more selective but less sensitive for tumor lesions 
than [18F]FDG, [11C]MET and [11C]choline. Use of somatostatin receptor ligands may be 
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limited to detecting meningiomas, while hypoxia markers are best suited for disease 
prognosis and predicting response to radiotherapy. Recent studies with choline-, acetate- 
and integrin-based PET probes seem encouraging but more work is needed to fully 
appreciate their potential. In conclusion, positron-labeled amino acids are showing highest 
general utility for staging and therapy management of gliomas, while other metabolic 
probes are undergoing validation to answer selected clinical questions such as assessment of 
hypoxia and angiogenesis. 
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